Cell-free DNA screening for trisomies 21, 18 and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of obstetrics and gynecology"
DOI: 10.1016/j.ajog.2022.01.019
Abstract: BACKGROUND Cell-free DNA (cfDNA) non-invasive prenatal screening for trisomy (T) 21, 18, and 13 has been rapidly adopted into clinical practice. However, prior studies are limited by lack of follow up genetic testing to confirm… read more here.
Keywords: dna; risk; genetic confirmation; risk aneuploidy ... See more keywords